肝细胞癌过继性细胞治疗的临床试验概况

为肝细胞癌武装 GPC3 CAR-T 细胞：多少才足够，下一步是什么？

Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?

NSUN2 介导的 m(5)C 修饰的代谢重编程通过限制 NK 细胞介导的细胞毒性促进肝细胞癌进展

Metabolic Reprogramming of NSUN2-Mediated m(5)C Modification Promotes the Progression of Hepatocellular Carcinoma by Restricting Natural Killer Cell-M

一种通过设计的抗免疫抑制纳米调节剂和射频消融有效治疗癌症的新型联合疗法

A novel combination therapy for effective treatment of cancer by designed anti-immunosuppressive nanoregulator and radiofrequency ablation.

基线循环和肿瘤γδ T 细胞及早期循环 CD8⁺PD1⁺扩增预测 HCC 中对 Atezolizumab-bevacizumab 的应答

Baseline circulating and tumor γδ T cells and early circulating CD8⁺PD1⁺ expansion predict response to Atezolizumab-bevacizumab in HCC.

高基线循环和肿瘤γδ T 细胞以及早期循环 CD8⁺PD-1⁺ T 细胞扩增与 AtezoBev 治疗下更好的结局相关。循环 CD8⁺TIGIT⁺细胞的早期增加与治疗耐药相关。

肿瘤芯片模型揭示并靶向巨噬细胞-NK 细胞互作以推进免疫治疗筛选

A tumor-on-a-chip model reveals and targets reciprocal macrophage-NK cell crosstalk to advance immunotherapy screening.

CPNE1 通过 STAT3-TGF-β信号通路促进肝细胞癌的干性并赋予其对 GPC3 CAR-T 细胞治疗的耐药性

CPNE1 promotes stemness and confers resistance to GPC3 CAR-T cell therapy in hepatocellular carcinoma via the STAT3-TGF-β signaling pathway.

这些发现表明 CPNE1 是 HCC 进展和免疫抑制的关键调控因子，突显了 CPNE1-STAT3-TGF-轴作为 HCC 中有前景的治疗靶点。